A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients

  • MacDonald, Mark Kowalski, Jocelyn Entwistle, Jeannick Cizeau, Demi Niforos, Shauna Loewen, Wendy Chapman
  • Drug Design Development and Therapy, November 2010, Taylor & Francis
  • DOI: 10.2147/dddt.s14071

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.2147/dddt.s14071